Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activating mutations in STAT3 and STAT5 differentially affect cellular proliferation and apoptotic resistance in multiple myeloma cells.

Cancer biology & therapy - 1 Feb 2004

Hodge David R, Xiao Weihua, Wang Li Hua, Li Dapei, Farrar William L

Abstract excerpt

Multiple Myeloma (MM) is a progressive malignancy with poor prognosis, commonly treated by the use of the glucocorticoid Dexamethasone. Myeloma cells resist Dexamethasone induced apoptosis when exposed to IL-6 or IGF-1, both of which are known to activate several signaling cascades. For the first time, we show the actual contribution of downstream mediators, i.e., activated STAT factors, independent of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Inflammatory Agents
Share to Dexamethasone

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Electrophoretic Mobility Shift Assay

Share to Fas Ligand Protein

Share to Milk Proteins

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Retroviridae

Share to STAT5 Transcription Factor

Source

Identifiers

PMID: 14726660
DOI: 10.4161/cbt.3.2.621

Genes

STAT3
FAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activating mutations in STAT3 and STAT5 differentially affect cellular proliferation and apoptotic resistance in multiple myeloma cells.PMID 14726660Read ↗

The effect of azacitidine on interleukin-6 signaling and nuclear factor- B activation and its in vitro and in vivo activity against multiple myelomaSemantic proximity Read ↗

Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis.Semantic proximity Read ↗

Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation.Semantic proximity Read ↗

Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors.Semantic proximity Read ↗

Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses.Semantic proximity Read ↗

The imbalance between Bim and Mcl‐1 expression controls the survival of human myeloma cellsSemantic proximity Read ↗

Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells.Semantic proximity Read ↗

Non-canonical role for the ataxia-telangiectasia-Rad3 pathway in STAT3 activation in human multiple myeloma cellsSemantic proximity Read ↗

Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myelomaSemantic proximity Read ↗

Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6.Semantic proximity Read ↗

Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells.Semantic proximity Read ↗

A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.